In a recent study posted to the bioRxiv* pre-print server, researchers investigated the complement component 1q (C1q) binding and subsequent complement activation by neutralizing antibodies (nAbs) ...

The story of Q32 Bio, a company that develops therapeutics for inflammatory and autoimmune diseases, started two decades ago. That's when V. Michael Holers, MD, a University of Colorado School of ...

Researchers identified several antibodies to the nucleocapsid protein from a convalescent COVID-19 patient. Tests found some can inhibit complement hyperactivation and could potentially lead to new ...

Newco Commit Biologics ApS has arrived on the scene after raising €16 million (US$17.2 million) in a seed round to advance bispecific antibodies that are designed to activate the complement system and ...

Complement activation in patients with AAV who are in remission may be reflective of ongoing renal scarring. Persistent complement activation during disease remission in antineutrophil cytoplasmic ...

True North Therapeutics, Inc., announced today a publication demonstrating that the company's C1s antibody prevents the destruction of human red blood cells exposed to plasma samples of patients with ...

TSP-1 reduced C3 and C5 cleavage and formation of the membrane attack complex, attenuating complement-mediated injury in AAV models. Complement activation is a relevant driver in the pathomechanisms ...

The earliest description of an incompatible hemolytic transfusion reaction dates to the experimental start of transfusion therapy in the mid-17th century. While treating a nobleman who had episodes of ...